

Physicians

Mohsin H. Ali, M.D.
Mohammed K. Barazi, M.D.
Daniel M. Berinstein, M.D.
Sonya Bryant, M.D.
Gordon A. Byrnes, M.D.
Rachel C. Chen, M.D.
Dal W. Chun, M.D.
Vinay N. Desai, M.D.
Brian K. Do, M.D.
Jordana G. Fein, M.D., M.S.
Richard A. Garfinkel, M.D.
Claudia G. Hooten, M.D.
J. Mingyi Huang, M.D.
T. Mark Johnson, M.D., FRCSC
Sundeep Kasi, M.D.
Reshma C. Katira, M.D.
Aziz A. Khanifar, M.D.
Michael M. Lai, M.D., Ph.D.
Eric S. Lee, M.D.
Joshua D. Levinson, M.D.
Mariam Mathai, M.D.
Alexander Melamud, M.D., M.A.
John R. Minarcik, M.D.
Michael H. Osman, M.D.
Sneha Padidam, M.D.
William B. Phillips, M.D.
Deborah A. Reid, M.D.
Gayatri S. Reilly, M.D.
Osama Sabbagh, M.D.
Reginald J. Sanders, M.D.
Cuong D. Vu, M.D.
Eric D. Weichel, M.D.
Lucy Xu, M.D.

Locations

MARYLAND

Annapolis
410.224.6680

Bowie
301.805.5395

Chevy Chase
301.656.8100

Clinton
301.868.8747

Columbia
410.997.4443

Greenbelt
301.441.4577

Rockville
301.315.2198

Silver Spring
301.495.2357

VIRGINIA

Alexandria
703.313.8822

Fairfax
703.698.9335

Fredericksburg
540.654.5333

Leesburg
703.421.0931

Manassas
703.257.9270

Reston
703-953-3826

Tysons Corner
703.564.4300

Woodbridge
844-RGW-DOCS

WASHINGTON, DC
Capitol Hill
202.331.1188

Semaglutide (Ozempic[®], Wegovy[®]) and its effect on diabetic retinopathy

Semaglutide (Ozempic, Wegovy) is an injectable glucagon-like peptide-1 (GLP-1) analogue that is approved for the treatment of type 2 diabetes (T2D) and obesity.¹ It works by slowing gastric emptying and reducing glucose absorption to reduce serum glucose levels.¹ This class of medication has gained significant traction over the past few years due to its significant and sustained improvements in glycated hemoglobin (HbA1c) and body weight vs placebo. In the SUSTAIN-6 trial, semaglutide showed a statistically significant 26% risk reduction in major adverse cardiovascular events when compared to placebo, along with an average weight loss of 10.8 pounds and lower average A1c by 1%.² These outcomes have made GLP-1 analogues a preferred agent for treatment of patients with diabetes¹, and the drugs have even become popularized as a weight loss drug by celebrities in mainstream media. However, despite its clear benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy (DR).

The SUSTAIN clinical trial program evaluated the efficacy and safety of semaglutide prior to its FDA approval. During these trials, semaglutide was found to be associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs placebo despite overall improvements in incidents of cardiovascular events and renal complications at the 2 year point.² Post publication analysis showed that patients who developed diabetic retinopathy complications were characterized by a longer mean diabetes duration, higher mean HbA1c levels at baseline, and greater likelihood to have been receiving insulin treatment at trial entry.³ Furthermore, there was a statistically significant higher risk for DR complications with semaglutide in patients with proliferative and non-proliferative DR at baseline.

The authors felt that much of the DR effect with semaglutide vs placebo was attributable to the magnitude and rapidity of HbA1c reduction during the first 16 weeks of treatment in patients,³ and was balanced out by the benefits of long term glucose control.

This paradoxical worsening of DR after a sudden drop in blood glucose is a well-documented phenomenon. The landmark DCCT (Diabetes Control and Complications Trial) found an association between better blood glucose control and risk of early worsening of DR.⁴ Another study looked at patients after intensive insulin treatment, pancreas transplant, or bariatric surgery, and found that 10% to 20% of patients had worsening of DR within three to six months—with twice that much for patients who already had advanced DR at baseline.⁵

The data shows that there is a real risk of DR progression with the use of semaglutide, but should we as ophthalmologists be concerned? And how should we be addressing this with our endocrinology and primary care physician colleagues?

Consensus in the retina community is that progression of DR is not a reason to keep the patients off these very effective medications.⁶ Whether patients progress in diabetic retinopathy or not, the advantages of overall reduction of cardiovascular disease should likely take priority. Additionally, many of these patients may have intermittent worsening of retinopathy for the first year or two, but often develop better control of the retinopathy long-term.⁶ The benefits of better glucose control systemically outweigh any local ocular risks.

Primary care physicians should be made aware that this drug might cause DR progression, and ideally all patients should get their routine DR screening prior to initiation of the drug. Once established with an ophthalmologist, increased screening for any diabetic retinopathy progression compared to normal re-examination timelines is recommended to catch any complications early. If the retina specialist is noting rapid progression on exam, earlier anti-VEGF may mitigate some of these changes. The PANORAMA trial showed us that anti-VEGF in patients with moderately severe to severe NPDR without diabetic macular edema can show a 2-step or greater improvement on the Diabetic Retinopathy Severity Scale, with significantly fewer vision-threatening complications.⁷

More guidance regarding this topic is being actively studied. The currently ongoing FOCUS trial is the first trial to evaluate the long-term effects of semaglutide on DR in patients with type 2 diabetes. This clinical trial will measure the presence of early treatment diabetic retinopathy level progression in 1500 patients with an A1c between 7% and 10%.⁸ Patients will be randomized to receive either placebo or semaglutide in addition to their diabetes medications, with the primary outcome of progression of DR and secondary outcomes of the incidence of treatment with anti-VEGF injections, laser photocoagulation, or vitrectomy. The study is estimated to conclude in 2026-2027.⁸

1. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. *Diabetes Care*. 2021;44(Supplement 1):S111-S124. doi:10.2337/dc21-S009
2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
3. Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. *Diabetes Obes Metab*. 2018;20(4):889-897. doi:10.1111/dom.13172
4. Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401.
5. Feldman-Billard S, Langer É, Massin P; Standards for screening and surveillance of ocular complications in people with diabetes SFD study group. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. *Diabetes Metab*. 2018 Feb;44(1):4-14. doi: 10.1016/j.diabet.2017.10.014.
6. <https://www.aao.org/eyenet/article/update-on-semaglutide-risks>
7. Brown DM, Wykoff CC, Boyer D, et al. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. *JAMA Ophthalmol*. 2021;139(9):946-955. doi:10.1001/jamaophthalmol.2021.2809
8. Novo Nordisk A/S. *Long-Term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes*. clinicaltrials.gov; 2021. Accessed April 30, 2023. <https://clinicaltrials.gov/ct2/show/NCT03811561>



At the forefront of clinical research

The Retina Group of Washington continuously conducts clinical trials at key locations. Our clinical research coordinators will be happy to discuss the inclusion/exclusion criteria or any other aspect of these studies with you or your patients. If you have any questions, please feel free to contact:

Katrina Arias - Chevy Chase, MD: 240.223.0896, karias@rgw.com

Nikel Gibbons - Chevy Chase, MD: 301.951.4319, ngibbons@rgw.com

Danielle Downer - Chevy Chase, MD: 240-223-0896, ddowner@rgw.com

Heena Ahluwalia - Fairfax, VA: 703-564-7519, hahluwalia@rgw.com

Flora Berrefas - Fairfax, VA: 703-698-9335, fberrefas@rgw.com

Rachel Rivera - Fairfax, VA: 703-698-9360 Ext 3512, rrivera@rgw.com

Enrolling Studies:

Wet AMD

Fairfax, VA

Coast – Opthea: A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

DME

Fairfax, VA

Notal Vision OCT: Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT

Upcoming Studies:

RVO

Fairfax, VA

Bayer Study: A Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg With Macula Edema due to Retinal Vein Occlusion

GA

Chevy Chase, MD

Parasol: Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham[1]Controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration

Washington Retina Symposium

SAVE THE DATE

October 21, 2023

7am-1pm

<https://retinasymposiumdc.com/>